Sirtex Doses First Patient in China Trial of Microsphere Radiation Therapy

Sirtex Medical, a division of China Grand Pharma and Healthcare, started a China trial of its selective internal radiation therapy in patients with hepatocellular carcinoma (HCC). One year ago, Sirtex filed an NDA in China for its SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy, for liver metastases from colorectal cancer. The Y-90 resin microspheres are designed to accumulate in the liver, where they deliver a 40-times larger dose of radiation without affecting normal tissue. In 2018, China 's CDH Holding paid $1.9 billion to acquire Sirtex. More details.... Share this with colleagues: // //